Korean Journal of Schizophrenia Research (대한조현병학회지)

Korean Society for Schizophrenia Research (대한조현병학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Delayed Clozapine Initiation on Acute Treatment Response in Treatment-Resistant Schizophrenia

클로자핀의 지연된 사용이 치료저항성 조현병 환자의 급성기 약물 반응에 미치는 영향

  • Yang, So Yung (Department of Psychiatry, National Health Insurance Service Ilsan Hospital) ;
  • Choi, Jung-Kyu (Institute of Health Insurance & Clinical Research, National Health Insurance Service Ilsan Hospital) ;
  • Park, Sunyoung (Department of Psychiatry, National Health Insurance Service Ilsan Hospital) ;
  • Park, Jaesub (Department of Psychiatry, National Health Insurance Service Ilsan Hospital)
  • 양소영 (국민건강보험 일산병원 정신건강의학과) ;
  • 최정규 (국민건강보험 일산병원 연구분석팀) ;
  • 박선영 (국민건강보험 일산병원 정신건강의학과) ;
  • 박재섭 (국민건강보험 일산병원 정신건강의학과)
  • Received : 2021.05.20
  • Accepted : 2021.07.06
  • Published : 2021.10.30
⟨ Previous Next ⟩

Abstract

Objectives: Recent studies have reported that delayed initiation of clozapine can affect clinical response in patients with treatment-resistant schizophrenia (TRS). This study aimed to explore the relationship between delayed initiation of clozapine and acute treatment response. Methods: Sixty-five inpatients with TRS who started clozapine for the first time were included through a retrospective chart review. Acute treatment response was defined as a 30% reduction in the Positive and Negative Syndrome Scale score or a Clinical Global Impression of Improvement score of 1 (very much improved) or 2 (much improved) at 4 weeks after initiating clozapine. Results: After meeting the TRS criteria, the mean delay for initiating clozapine was approximately 13.8 months. The delay was shorter in patients who showed a better response to clozapine in logistic regression analysis (p=0.037). Conclusion: Our findings suggest that reducing the delay in initiating clozapine increases the effectiveness of clozapine in patients with TRS.

Keywords

Acknowledgement

본 연구는 국민건강보험 일산병원의 연구비 지원으로 이루어졌음(NHIMC2020CR078).

References

  1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(2 Suppl):1-56. https://doi.org/10.1176/appi.ajp.161.1.1
  2. Lally J, Gaughran F. Treatment resistant schizophrenia-review and a call to action. Ir J Psychol Med 2019;36:279-291. https://doi.org/10.1017/ipm.2018.47
  3. Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-229. https://doi.org/10.1176/appi.ajp.2016.16050503
  4. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017;17:1-14. https://doi.org/10.1186/s12888-016-1163-4
  5. National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in adults: treatment and management. London: National Institute for Health and Care Excellence (UK);2014.
  6. Lee K. Treatment-Resistant Schizophrenia: terminology and Clinical Features. Korean J Schizophr Res 2020;23:45-50. https://doi.org/10.16946/kjsr.2020.23.2.45
  7. Kinon BJ. The group of treatment resistant schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry 2019;9:757. https://doi.org/10.3389/fpsyt.2018.00757
  8. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154:475-482. https://doi.org/10.1176/ajp.154.4.475
  9. Schennach R, Riedel M, Musil R, Moller HJ. Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78. https://doi.org/10.9758/cpn.2012.10.2.78
  10. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
  11. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64:5-19. https://doi.org/10.4088/JCP.v64n0301
  12. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and highdose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-285. https://doi.org/10.4088/JCP.v69n0214
  13. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962. https://doi.org/10.1016/S0140-6736(13)60733-3
  14. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957-965. https://doi.org/10.1177/0269881108093588
  15. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378. https://doi.org/10.3109/15622975.2012.696143
  16. Norman R, Lecomte T, Addington D, Anderson E. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. Can J Psychiatry 2017;62:617-623. https://doi.org/10.1177/0706743717719894
  17. Taylor DM, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64:30-34. https://doi.org/10.4088/JCP.v64n0107
  18. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of anti-psychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-485. https://doi.org/10.1192/bjp.bp.111.105833
  19. Kim SH. Current status of clozapine for treatment-resistant schizophrenia. Korean J Schizophr Res 2021;24:1-7. https://doi.org/10.16946/kjsr.2021.24.1.1
  20. Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig 2014;34:203-211. https://doi.org/10.1007/s40261-013-0166-x
  21. Kang SH, Lee HW. Prescribing pattern of clozapine and clinical factors associated with discontinuation of clozapine. Korean J Schizophr Res 2019;22:1-7. https://doi.org/10.16946/kjsr.2019.22.1.1
  22. Okhuijsen-Pfeifer C, Sterk A, Horn I, Terstappen J, Kahn R, Luykx J. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev 2020;111:246-252. https://doi.org/10.1016/j.neubiorev.2020.01.017
  23. Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med 2021;51:376-386. https://doi.org/10.1017/S0033291721000246
  24. Altamura A, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 2001;52:29-36. https://doi.org/10.1016/S0920-9964(00)00187-0
  25. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804. https://doi.org/10.1176/appi.ajp.162.10.1785
  26. Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res 2018;268:114-122. https://doi.org/10.1016/j.psychres.2018.06.070
  27. Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020;270:11-22. https://doi.org/10.1007/s00406-019-01053-6
  28. Ucok A, Cikrikcili U, Karabulut S, Salaj A, Ozturk M, Tabak O, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol 2015;30:290-295. https://doi.org/10.1097/YIC.0000000000000086
  29. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci 2020;18:386-394. https://doi.org/10.9758/cpn.2020.18.3.386
  30. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261. https://doi.org/10.1093/schbul/13.2.261
  31. Guy W. ECDEU assessment manual for psychopharmacology. Rockville: U. S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs;1976.
  32. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325. https://doi.org/10.1038/sj.npp.1301147
  33. Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 2017;250:65-70. https://doi.org/10.1016/j.psychres.2017.01.064
  34. Thien K, O'Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry 2019;13:18-23. https://doi.org/10.1111/eip.12683
  35. Cho JW, Kim WH, Shin JH, Kim JH, Lee JS, Bae JN, et al. Reason for clozapine discontinuation. Korean J Schizophr Res 2016;19:17-24. https://doi.org/10.16946/kjsr.2016.19.1.17
  36. Hayhurst KP, Brown P, Lewis SW. Postcode prescribing for schizophrenia. Br J Psychiatry 2003;182:281-283. https://doi.org/10.1192/bjp.182.4.281
  37. Cirulli G. Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. Psychiatr Bull 2005;29:377-380. https://doi.org/10.1192/pb.29.10.377
  38. Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. B J Psych Bull 2019;43:8-16.
  39. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16-24. https://doi.org/10.1111/acps.12193
  40. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48. https://doi.org/10.1023/A:1023228626309
  41. Laker M, Duffett R, Cookson J. Long-term outcome with clozapine: comparison of patients continuing and discontinuing treatment. Int Clin Psychopharmacol 1998;13:75-78. https://doi.org/10.1097/00004850-199803000-00003
  42. Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381. https://doi.org/10.1093/oxfordjournals.schbul.a033333
  43. Jeon YH, Jung MY. The determinants of the length of stay in hospital for schizophrenic patients: using from the Health Insurance Claim Data of inpatients. J Digit Converg 2020;18:257-263.
  44. Conley RR, Carpenter Jr WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-1247. https://doi.org/10.1176/ajp.154.9.1243